| Name | Title | Contact Details |
|---|
Imara Inc. is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.
Dewpoint Therapeutics is leveraging a transformative shift in the understanding of cellular biology regulation to discover and advance breakthrough small-molecule therapeutics.
GluStitch, Inc. is a Delta, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Cradle Genomics, our mission is to provide knowledge that helps every pregnancy.
twoXAR is an artificial intelligence-driven drug discovery company.